Ypsomed Holding AG
YPSN.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.74B
Close$
$-153.58
141.8% downside
Current Fair Value
141.8% downsideOvervalued by 141.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.74 Billion |
|---|---|
| Enterprise Value | $6.00 Billion |
| Dividend Yield | $4.40 (1.21%) |
| Earnings per Share | $16.31 |
| Beta | 0.81 |
| Outstanding Shares | 13,543,700 |
Return
| Return on Equity | 35.51% |
|---|---|
| Return on Assets | 19.73% |
| Return on Invested Capital | 30.67% |
Valuation & Multiples
| P/E Ratio | 22.21 |
|---|---|
| PEG | 11.01 |
| Price to Sales | 4.54 |
| Price to Book Ratio | 6.68 |
| Enterprise Value to Revenue | 5.43 |
| Enterprise Value to EBIT | 18.72 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$5.15
Average shareholder expectationRevenue Estimate
$314.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ypsomed Holding AG
2,025 employees
CEO: Simon Michel Ypsomed Holding AG, along with its affiliates, specializes in the design, production, and sale of advanced injection and infusion delivery systems for pharmaceutical and biotechnology enterprises. The company structures its activities in...